Drug Interactions between Entyvio and Humira

GENERALLY AVOID: The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. No data are available on the use of TNF blockers specifically with vedolizumab. Concomitant use with other immunosuppressants such as azathioprine or mercaptopurine has been reported to increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL), which has primarily been reported in adolescents and young adults receiving treatment for Crohn's disease or ulcerative colitis. Cases of HSTCL have also occurred during use of these agents alone. Because individuals with rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, or plaque psoriasis may be more likely to develop lymphoma than the general population, it is difficult to assess the added risk of TNF blockers or other immunosuppressants.

MANAGEMENT: The safety and efficacy of vedolizumab in combination with TNF blockers have not been established. Concomitant use should be avoided.